Guardant Health Stock Price, News & Analysis

Guardant Health (GH) announced a settlement with Foundation Medicine regarding digital sequencing technology patents. Foundation Medicine will pay Guardant Health $25 million and future royalties. This agreement results in the dismissal of all pending patent litigation between the two companies. Guardant Health's Co-CEO, Helmy Eltoukhy, emphasized the significance of this settlement, highlighting the recognition of their scientific discoveries and strong intellectual property rights.

Guardant Health, a leader in precision oncology, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. The presentation will occur on January 10 at 12:00 p.m. PT / 3:00 p.m. ET. Investors can access the live and archived webcast through the company’s website. Guardant Health focuses on combating cancer using proprietary tests, including Guardant360® and Guardant Reveal™, aiming to improve outcomes and reduce healthcare costs across the cancer care continuum.

Guardant Health (NASDAQ: GH) announced it has reached a milestone in the ECLIPSE study, enrolling 12,750 patients to evaluate its LUNAR-2 blood test for colorectal cancer (CRC) detection. The study aims to support a PMA submission to the U.S. FDA, contingent on positive results. Colorectal cancer screening rates are currently low, and LUNAR-2 seeks to address this by providing a non-invasive blood test to improve access. This milestone reflects the commitment of researchers and participants during challenging times.

Guardant Health (NASDAQ: GH) has announced new data on its Guardant360 liquid biopsy test, presented at the 2021 San Antonio Breast Cancer Symposium. The studies reveal that patients with BRCA1/2 reversion mutations had worse survival outcomes when treated with PARP inhibitors compared to those without. Another study found no significant difference in treatment outcomes for advanced breast cancer patients with PIK3CA mutations regardless of mutation clonality when treated with alpelisib. These findings underscore the utility of the Guardant360 assay in guiding targeted therapy.

Guardant Health (Nasdaq: GH) announced a study published in Nature Medicine demonstrating the effectiveness of the Guardant360 test for guiding treatment in HER2-driven metastatic colorectal cancer. Conducted by the National Cancer Center Hospital East in Japan, the study shows that the test accurately selects patients for HER2-targeted therapy and identifies genetic alterations predicting treatment resistance. The Guardant360 test has been widely accepted, with over 150,000 tests performed and significant clinical validation through peer-reviewed publications.

Guardant Health (Nasdaq: GH) will participate in the 2021 Stifel Healthcare Conference virtually. The management is set for a fireside chat on November 15 at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties can access the live and archived webcast via the company’s website. Guardant Health, a leader in precision oncology, focuses on innovative tests and analytics for cancer care, including its Guardant360 and Guardant Reveal tests.

Guardant Health (GH) reported third quarter 2021 revenue of $94.8 million, a 27% increase from the prior year. Clinical testing revenue grew 35% with 22,806 tests performed, while biopharmaceutical tests rose 58% to 4,839. The gross profit reached $64 million, with a gross margin of 67%, though operating expenses rose 34% to $171.3 million, leading to a net loss of $107.5 million. Full-year revenue guidance is projected between $360 million and $370 million.

Guardant Health (GH) has partnered with The Royal Marsden NHS Foundation Trust to establish an in-house liquid biopsy testing service, enhancing cancer diagnostics in the UK. This facility, set to operationalize by the end of 2022, will enable rapid and precise diagnostic testing for late-stage cancer patients. Guardant Health’s liquid biopsy tests are pivotal in guiding treatment decisions and facilitating clinical trials. With 375,000 new cancer cases reported in the UK from 2016-2018, this collaboration aims to improve patient outcomes through personalized treatment approaches.

Guardant Health's LUNAR-2 blood test shows promising results for colorectal cancer screening, achieving 96% sensitivity and 94% specificity in a study presented at the American College of Gastroenterology Annual Scientific Meeting.

Conducted on a cohort of 699 patients, the test particularly excels in detecting early-stage cancers, reaching 93% sensitivity for Stage 1 and 2 CRC. A larger trial, ECLIPSE, is underway to further validate these findings. Guardant aims to provide a non-invasive, easy-to-use alternative for CRC screening, potentially improving patient outcomes amidst declining screening rates.